NEW YORK, October 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., ...
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.